Treatment guidelines in psoriatic arthritis

Area of Science:

• Rheumatology
• Dermatology
• Clinical Practice Guidelines

Background:

• Psoriatic arthritis (PsA) is a multifaceted inflammatory condition affecting both the musculoskeletal system and skin.
• Therapeutic strategies for PsA have undergone significant evolution in the last decade.
• Clinical practice guidelines are essential tools for clinicians to incorporate updated knowledge into patient care.

Purpose of the Study:

• To compare current treatment recommendations for psoriatic arthritis (PsA).
• To analyze guidelines from the ACR/NPF (2018), EULAR (2015), and GRAPPA (2015).
• To identify commonalities and divergences in PsA management strategies across different organizational scopes.

Main Methods:

• A comparative review of published clinical practice guidelines for PsA treatment.
• Analysis focused on guidelines from one national (ACR/NPF), one regional (EULAR), and one international (GRAPPA) body.
• Examination of the development process and specific recommendations within each guideline set.

Main Results:

• The review identifies key similarities and differences in the treatment algorithms proposed by the ACR/NPF, EULAR, and GRAPPA.
• Specific variations in recommendations for pharmacologic and non-pharmacologic interventions are noted.
• The analysis provides insight into the consensus and discrepancies in expert opinion on PsA management.

Conclusions:

• Comparative analysis of PsA guidelines reveals both convergence and divergence in recommended treatment pathways.
• Understanding these differences is crucial for clinicians managing PsA patients.
• Further harmonization of international guidelines may enhance consistent patient care for psoriatic arthritis.